Literature DB >> 11278773

Insulin and insulin-like growth factor I receptors utilize different G protein signaling components.

S Dalle1, W Ricketts, T Imamura, P Vollenweider, J M Olefsky.   

Abstract

We examined the role of heterotrimeric G protein signaling components in insulin and insulin-like growth factor I (IGF-I) action. In HIRcB cells and in 3T3L1 adipocytes, treatment with the Galpha(i) inhibitor (pertussis toxin) or microinjection of the Gbetagamma inhibitor (glutathione S-transferase-betaARK) inhibited IGF-I and lysophosphatidic acid-stimulated mitogenesis but had no effect on epidermal growth factor (EGF) or insulin action. In basal state, Galpha(i) and Gbeta were associated with the IGF-I receptor (IGF-IR), and after ligand stimulation the association of IGF-IR with Galpha(i) increased concomitantly with a decrease in Gbeta association. No association of Galpha(i) was found with either the insulin or EGF receptor. Microinjection of anti-beta-arrestin-1 antibody specifically inhibited IGF-I mitogenic action but had no effect on EGF or insulin action. beta-Arrestin-1 was associated with the receptors for IGF-I, insulin, and EGF in a ligand-dependent manner. We demonstrated that Galpha(i), betagamma subunits, and beta-arrestin-1 all play a critical role in IGF-I mitogenic signaling. In contrast, neither metabolic, such as GLUT4 translocation, nor mitogenic signaling by insulin is dependent on these protein components. These results suggest that insulin receptors and IGF-IRs can function as G protein-coupled receptors and engage different G protein partners for downstream signaling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11278773     DOI: 10.1074/jbc.M010884200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  38 in total

1.  GRK2 is an endogenous protein inhibitor of the insulin signaling pathway for glucose transport stimulation.

Authors:  Isao Usui; Takeshi Imamura; Hiroaki Satoh; Jie Huang; Jennie L Babendure; Christopher J Hupfeld; Jerrold M Olefsky
Journal:  EMBO J       Date:  2004-07-08       Impact factor: 11.598

2.  Engagement of β-arrestin by transactivated insulin-like growth factor receptor is needed for V2 vasopressin receptor-stimulated ERK1/2 activation.

Authors:  Geneviève Oligny-Longpré; Maithé Corbani; Joris Zhou; Mireille Hogue; Gilles Guillon; Michel Bouvier
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-09       Impact factor: 11.205

3.  Antipsychotic drugs activate the C. elegans akt pathway via the DAF-2 insulin/IGF-1 receptor.

Authors:  Kathrine R Weeks; Donard S Dwyer; Eric J Aamodt
Journal:  ACS Chem Neurosci       Date:  2010-03-25       Impact factor: 4.418

Review 4.  Beyond desensitization: physiological relevance of arrestin-dependent signaling.

Authors:  Louis M Luttrell; Diane Gesty-Palmer
Journal:  Pharmacol Rev       Date:  2010-04-28       Impact factor: 25.468

Review 5.  β-Arrestins: multifunctional signaling adaptors in type 2 diabetes.

Authors:  Xiaotao Feng; Wenjian Wang; Jibo Liu; Yi Liu
Journal:  Mol Biol Rep       Date:  2010-11-18       Impact factor: 2.316

Review 6.  Heterotrimeric G protein signaling via GIV/Girdin: Breaking the rules of engagement, space, and time.

Authors:  Nicolas Aznar; Nicholas Kalogriopoulos; Krishna K Midde; Pradipta Ghosh
Journal:  Bioessays       Date:  2016-02-16       Impact factor: 4.345

7.  IGF-1 activates a cilium-localized noncanonical Gβγ signaling pathway that regulates cell-cycle progression.

Authors:  Celine Yeh; Aiqun Li; Jen-Zen Chuang; Masaki Saito; Alfredo Cáceres; Ching-Hwa Sung
Journal:  Dev Cell       Date:  2013-08-15       Impact factor: 12.270

Review 8.  Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Authors:  Terry J Smith; Joseph A M J L Janssen
Journal:  Endocr Rev       Date:  2019-02-01       Impact factor: 19.871

9.  Insulin induces heterologous desensitization of G-protein-coupled receptor and insulin-like growth factor I signaling by downregulating beta-arrestin-1.

Authors:  Stéphane Dalle; Takeshi Imamura; David W Rose; Dorothy Sears Worrall; Satoshi Ugi; Christopher J Hupfeld; Jerrold M Olefsky
Journal:  Mol Cell Biol       Date:  2002-09       Impact factor: 4.272

10.  β-arrestin-selective G protein-coupled receptor agonists engender unique biological efficacy in vivo.

Authors:  Diane Gesty-Palmer; Ling Yuan; Bronwen Martin; William H Wood; Mi-Hye Lee; Michael G Janech; Lam C Tsoi; W Jim Zheng; Louis M Luttrell; Stuart Maudsley
Journal:  Mol Endocrinol       Date:  2013-01-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.